08:00 , Jan 24, 2011 |  BioCentury  |  Finance

Less VC, more SBIR

Altor BioScience Corp. and its investors have structured a financing strategy that keeps the company eligible for Small Business Innovation Research grants, thus reducing dilutive equity funding. Investors hope last week's $10.3 million series D...
08:00 , Dec 17, 2009 |  BC Innovations  |  Tools & Techniques

A call to arms

A paper by Genmab A/S researchers proposing a mechanism by which antibodies with IgG4 backbones may elicit side effects caught the attention of PanGenetics B.V., which is running a Phase I psoriatic arthritis trial of...
08:00 , Feb 18, 2008 |  BC Week In Review  |  Company News

Altor BioScience, Genentech deal

Altor BioScience Corp., Miramar, Fla.   Genentech Inc. (NYSE:DNA), South San Francisco, Calif.   Business: Cancer, Pulmonary, Autoimmune   Genentech granted Altor exclusive, worldwide rights to develop and commercialize two antibodies: ALT-836 (formerly TNX-832), a chimeric...
08:00 , Feb 18, 2008 |  BC Week In Review  |  Clinical News

ALT-836: Phase II start

By year end, Altor will begin a placebo-controlled Phase II trial in 120 patients. Last week, the company licensed exclusive rights to the compound from Genentech Inc. (NYSE:DNA, South San Francisco, Calif.). Altor BioScience...
08:00 , Feb 18, 2008 |  BioCentury  |  Finance

Ebb & Flow

Creating a series of next generation Genentechs is not exactly a modest goal, but that is what The Column Group is setting out to do. In mid-April, the firm expects to close its first fund...
03:01 , Feb 13, 2008 |  BC Extra  |  Company News

Altor in-licensing Genentech antibodies

Genentech (NYSE:DNA) granted Altor (Miramar, Fla.) exclusive, worldwide rights to develop and commercialize two antibodies: ALT-836 (formerly TNX-832), a chimeric antibody against tissue factor that is expected to begin Phase II testing this year to...
08:00 , Nov 13, 2006 |  BC Week In Review  |  Company News

Genentech, Tanox deal

DNA said it plans to acquire TNOX for $20 per share in cash, or $919 million. The offer is a 47% premium to TNOX's $13.64 closing price on Nov. 9, before the deal was announced....
02:20 , Nov 10, 2006 |  BC Extra  |  Top Story

Genentech to acquire Tanox

DNA said late Thursday that it plans to acquire TNOX for $20 per share in cash, or $919 million. The deal price is a 47% premium to TNOX's close of $13.64 on Thursday. DNA said...
07:00 , Apr 4, 2005 |  BC Week In Review  |  Company News

Tanox, Sunol deal

TNOX agreed to acquire Sunol's tissue factor antagonist program to treat inflammatory diseases and cancer for stock and cash. TNOX will issue 800,000 shares and pay $6 million to Sunol. Based on TNOX's close...
01:54 , Mar 29, 2005 |  BC Extra  |  Company News

Tanox, Sunol tissue factor deal

TNOX agreed to acquire for stock and cash Sunol Molecular's tissue factor antagonist program to treat inflammatory diseases and cancer. TNOX will issue 800,000 shares and pay $6 million to Sunol Molecular (Miramar, Fla.). Based...